uniQure (QURE) Q2 2026: EPS Miss Masked by Pipeline Milestones
As seen on the 24/7 Wall St. homepage on July 29, 2026.
uniQure's gene therapy pipeline pivots into focus as the company plans a Huntington's disease BLA submission in Q3, four-year clinical data due in September, and a 2030 cash runway into place despite an EPS miss tied to foreign currency swings and warrant fair value losses.
Continue ReadingShow less
uniQure reported a Q2 2026 loss of $1.22 per share, coming in about 72% worse than the consensus estimate of roughly $0.71. The shortfall was driven by foreign currency swings and warrant fair value losses rather than deteriorating operations, a distinction worth keeping in mind when sizing up the headline number. On the revenue side, the company actually outpaced expectations, posting $5.84 million against an estimate of $4.71 million — a beat of about 24%.
The more consequential story sits in the pipeline. uniQure is planning a Biologics License Application submission for its Huntington's disease gene therapy in Q3, a regulatory step that would mark a pivotal transition from clinical-stage company toward potential commercialization. Four-year clinical data from the Huntington's program is expected in September, which should give investors a clearer picture of durability ahead of any FDA review.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
Underpinning the near-term risk profile is a cash runway the company has extended into 2030, providing a meaningful buffer as it navigates the BLA process and awaits the data readout. Looking at the recent earnings history, uniQure's results have been uneven quarter to quarter — swinging between beats and misses — so the non-cash charges behind this quarter's miss are an important qualifier for how the underlying business is actually progressing.
Mentioned: QURE